Orbimed Advisors Trims $125 After Breakout Year in Biotech
A major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
Converting a 401k to a retirement plan can be a strategic move. Learn when it's the right time to make that transition.
20,599 articlesA major biotech stake shift signals evolving risk appetite. We break down the $125 million trim by ORBIMED Advisors, ...
When a prominent hedge fund reports selling a large block of shares, it sparks questions about the stock’s future. Th...
A major fund trimmed a sizable stake in Manhattan Associates as the stock pulled back sharply. This article breaks do...
Investors are watching Micron Technology closely as AI-driven demand reshapes memory markets. This guide explains whe...
Institutional buyers are flocking to STRC, Strategy’s variable-rate perpetual preferred stock, driving an 11% yield a...
A practical, no-fluff look at national health investors (nhi) after its Q4 update. We break down occupancy, rent coll...
Escalating tensions around Iran are triggering market swings and rising energy costs. This report explains how the se...
A confident march for Nvidia stock could hinge on one powerful trend. This article breaks down the single reason reas...
EOS Energy Enterprises sparked a notable move in today’s trading. This article breaks down the possible catalysts beh...
Palantir stock investors just got new cues from the Street. This guide explains what the headlines might mean, how to...
A high-profile insider sale at Urban Outfitters has investors weighing risk and opportunity. Learn how to interpret t...
A leading infrastructure stock surged 124% in the past year, even as a major fund dumped roughly $38 million of its s...